Clinical Trials

Resistant sarcomas slowed by new therapeutic combination

By

A new therapeutic combination to combat resistant sarcomas has shown promise in a trial.

US Food and Drug Administration fast-tracks novel leukemia therapy

US Food and Drug Administration fast-tracks novel leukemia therapy

An experimental immunotherapy agent was placed on the US Food and Drug Administration's fast track to market approval after overwhelmingly positive results were seen in patients with leukemia. In early trials, 89% of patients who received the personalized immunotherapy known as CTL019 saw their cancers disappear.

Surgical Biopsy Safe for Some Patients With Late-Stage Lung Cancer

Surgical Biopsy Safe for Some Patients With Late-Stage Lung Cancer

Surgical biopsy is safe for certain late-stage lung cancer patients and could improve their chances of getting treated with newer types of drugs that target cancer-related genetic mutations.

Direct injection treatment of pancreatic cancer shows encouraging results

Direct injection treatment of pancreatic cancer shows encouraging results

Results of a phase I clinical trial of a vaccine therapy for pancreatic cancer indicate the treatment is well tolerated; in addition, it suggests that the vaccine stabilizes the disease for a period of time.

Study demonstrates improved diagnosis and outcomes with LDCT

By

A study using a 5-year LDCT screening protocol showed good adherence and patient survival outcomes in persons at high risk of developing lung cancer.

Developing an innovative online cancer information center

Developing an innovative online cancer information center

By

An increasingly complex environment for cancer care and research highlights the need to streamline access to cancer information, especially clinical trials.

Phase 1 trials begin for first-in-class anticancer drug

By

Clinical trials have begun for PFK-158, a small-molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials.

Community Cancer Centers Program Participation Increases Rural Clinical Trial Enrollment

Community Cancer Centers Program Participation Increases Rural Clinical Trial Enrollment

By

Expanding the National Cancer Institute (NCI) Community Cancer Centers Program within a rural community can increase the number of patients enrolled in clinical trials

Shared Decision-making Ups Clinical Trial Participation, But Few Still Enroll

Shared Decision-making Ups Clinical Trial Participation, But Few Still Enroll

By

Fewer than 5% of adults with cancer enroll in clinical trials, despite such enrollment being critical to evaluate new therapies.

Experimental treatment shows early promise for advanced neuroblastoma in children

By

Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody.

Immunotherapy: A New Hope for NSCLC [Video]

Created by the Society for Immunotherapy of Cancer (SITC), this video follows a sample patient's journey from the diagnosis of NSCLC through the process of learning about cancer immunology.

Risk-assessment approach outlined for biomarker-driven clinical trials

By

A practical risk-management approach for effectively integrating biomarkers into cancer clinical trials has been outlined by a working group.

New experimental drug may be game-changer for acute myeloid leukemia

By

Clinical trials for a new experimental drug, CPX-351, to treat acute myeloid leukemia are very promising, according to researchers.

Experts weigh in on managing elderly patients with NSCLC

By

Approximately half of all patients with a diagnosis of non-small cell lung cancer are age 70 years or older, yet elderly patients are not well represented in clinical trials.

Intervention fidelity essential for clinical trials

By By

ANAHEIM, CALIFORNIA—Intervention fidelity is an essential element of randomized, clinical trials. To illustrate this point, one researcher described how intervention fidelity was incorporated into her clinical trial evaluating self-administration of acupressure for persistent cancer-related fatigue in breast cancer.

PD-L1 protein levels predict response to immunotherapy in lung cancer patients

By

Among patients with non-small cell lung cancer treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes.

Investigational drug benefits subgroup of patients with head and neck cancer

By

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck may benefit from treatment with the investigational drug dacomitinib.

First-in-class metabolism drug shown to be clinically active against advanced blood cancers

By

AG-221, a novel inhibitor of isocitrate dehydrogenase 2-mutant metabolic enzyme, showed early promise in patients with advanced and refractory blood cancers harboring IDH2 mutations.

New drug shows promise in early studies for metastatic breast cancer

New drug shows promise in early studies for metastatic breast cancer

By

The new oral drug LY2835219, an inhibitor of cyclin-dependent kinases 4 and 6, showed early promise as monotherapy for patients with metastatic breast cancer.

Early promise against melanoma from new antibody-drug conjugate

By

The investigational drug DEDN6525A, a new antibody-drug conjugate, was safe, tolerable, and showed hints of activity against three forms of melanoma: cutaneous, mucosal, and ocular.

Subset of patients with breast cancer patients will most likely benefit from neratinib

By

The I-SPY 2 trial identified a neo-adjuvant regimen containing the investigational drug neratinib and standard chemotherapy to be beneficial for HR-negative, HER2-positive primary (nonmetastatic) breast cancer patients.

New immunotherapy promising for advanced melanoma

New immunotherapy promising for advanced melanoma

By

A new type of immunotherapy that directs patients' immune responses toward tumor cell killing, IMCgp100, showed efficacy in some patients with advanced melanoma.

Epigenetic therapy clinically active against several blood cancers

Epigenetic therapy clinically active against several blood cancers

By

Patients with a variety of hematologic cancers benefited from treatment with OTX015, a member of a new class of investigational epigenetic therapies that block the activity of bromodomain and extraterminal (BET)-bromodomain proteins.

Clinical trial success enhanced by biomarker- and receptor-targeted therapies in NSCLC

By

Although the cumulative success rate for new agents for advanced NSCLC is lower than the industry-estimated rate, clinical trial success has been substantially increased by biomarker- and receptor-targeted therapies.

Assessing HRQOL is valuable in small-cell lung cancer trials

By

Health-related quality of life assessment in randomized clinical trials in small cell lung cancer provides added information in studies where the treatment arms do not differ in terms of efficacy.

Clinical trial data on metformin for cancer are showing conflicting results

By

The diabetes drug metformin is undergoing investigation as a potential treatment for different cancers in numerous clinical trials, but results vary.

Endoxifen promising as treatment for ER-positive breast cancer

By

A phase 1 trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe and provides early evidence for antitumor activity.

Innovative clinical trial design is a new paradigm in breast cancer research

By

The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.

Drug induces morphologic, molecular, and clinical remissions in myelofibrosis

By

Imetelstat, a novel telomerase-inhibiting drug, has been found to induce morphologic, molecular, and clinical remissions in some patients with myelofibrosis, according to a new study. The results were presented at the 2013 ASH Annual Meeting, in New Orleans.

Low-intensity therapy for Burkitt lymphoma is highly effective

By

Adult patients with Burkitt lymphoma had excellent long-term survival rates—upwards of 90%—following treatment with low-intensity chemotherapy regimens, according to a new clinical trial finding.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs